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Summary Pleural effusion samples were obtained from 55 patients with malignant disease, including patients
with primary lung cancers and those with a variety of other tumours metastatic to the pleura. The effusions
were assayed for the presence of hepatocyte growth factor/scatter factor (HGF/SF), by both ELISA and
bioassay. The presence of malignant cells in the effusions was also assessed. Detectable amounts of the factor,
as judged by both criteria, were found in over 90% of all the effusions, including those from patients with a
wide variety of carcinomas and also lymphomas. A wide range of HGF/SF levels were found for all tumour
classes, some effusions containing high levels above 4 ng ml-. It is concluded that tumours within the pleura
and adjacent lung tissue are usually exposed to biologically significant levels of HGF/SF.
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There is now a large body of evidence demonstrating that a
wide variety of cytokines and growth factors modulate the
growth and dissemination of many tumour cell types. Among
these are a number of growth factors that also have marked
effects on cell motility and on cell adhesional properties
(reviews Stoker and Gherardi, 1991; Warn, 1994). Scatter
factor was the first such factor to be identified as capable of
rupturing cell-cell adhesions and thus dissociating or
scattering epithelial cell colonies in culture (Stoker and
Perryman, 1985; Stoker et al., 1987). Sequence analysis
(Weidner et al., 1991) demonstrated scatter factor to be the
same molecule as hepatocyte growth factor, a strong growth
promoter for many epithelial cell types and also endothelial
cells (reviews Matsumoto et al., 1993; Tsubouchi et al., 1993).
The molecule is now commonly referred to as hepatocyte
growth factor/scatter factor (HGF/SF). HGF/SF is a
heterodimeric protein with an Mr of approximately
90 000 Da consisting of a 62 kDa A-chain and a 34/32 kDa
B-chain (review Gherardi et al., 1993). It scatters a wide
variety of normal and tumour-derived epithelial cell lines and
also stimulates the migration of tumour cell lines into
collagen gels, thus enhancing their invasive properties in
vitro (Weidner et al., 1990). The receptor for HGF/SF has
been identified to be the product of the c-met proto-oncogene
(Bottaro et al., 1991; Naldini et al., 1991), a transmembrane
glycoprotein with a tyrosine kinase domain forming a key
part of the internal structure. A wide range of tumour types
have been found to have raised levels of c-met (Di Renzo et
al., 1991; Prat et al., 1991). Of these tumours, the highest
levels were seen in human thyroid cancers, where there was
frequently more than a 100-fold amplification compared with
normal thyroid tissue.
The above properties suggest that HGF/SF may be
involved in cancer development. In a previous study
(Kenworthy et al., 1992) we demonstrated that HGF/SF
could be identified in a significant proportion of a small
number of pleural effusion fluids obtained from patients with
metastatic spread to the pleura. Here we extend this work to
a much larger group of patients with primary or secondary
tumours of a variety of types, including lymphomas.
Materials and methods
Collection andprocessing ofsamples
Pleural effusion fluid was obtained by aspiration and the cells
were removed by centrifugation for subsequent cytopatholo-
gical investigation. Between 5 and 20 ml of fluid was
routinely obtained, aliquotted and frozen until assayed. For
each patient, the records of the Department of Histopathol-
ogy/Cytopathology were examined and, when appropriate,
the case notes were reviewed.
ELISA
Pleural effusion samples were tested for the presence ofHGF/
SF using the enzyme-linked immunosorbent assay (ELISA)
developed by Tsubouchi et al. (1991). This is a sandwich
method consisting of three steps, originally developed for the
detection of HGF/SF in the serum ofpatients with acute liver
failure. It has a detection limit of approximately 0.2 ng ml-'
and is highly specific for human HGF/SF.
Scattering bio-assay
This was carried out following the method of Stoker and
Perryman (1985). Samples (150 Mil) of each pleural effusion
sample were serially diluted 2-fold with 150 pl of Dulbecco's
modified Eagle medium (DMEM) +5% fetal calf serum and
approximately 5 x 103 MDCK cells in 150 ,l DMEM then
added. After 24 h growth the cells were fixed in formol -
saline, stained with Loffler's methylene blue and the lowest
sample concentration determined at which scattering
occurred. Two investigators independently determined the
end point. Human blood serum samples were also assayed
but were found in general to inhibit the normal spreading
and growth of MDCK cells.
Protein concentration determination
The protein concentration of all the pleural effusion samples
was measured by the method of Bradford (1976).
Results
Pleural effusion fluid samples were obtained from 55 cancer
patients (28 male and 27 female) with a mean age of 66 years
(range 33-90 years). Tables I and II split the data into five
main categories depending on the tumour classes found:
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Table I HGF/SF levels in pleural effusion fluids obtained from patients with primary lung carcinoma or malignant mesothelioma
No. ofpatients No. ofpatients where Median HGF/SF levels Mean HGF/SF
(no. ofsamples malignant cells ngmrl (range in level per mg of
Tumour type in brackets) found in effusions brackets) protein
Primary lung carcinomas
Adenocarcinoma 5(5) 5 0.48(0.59-0.28a) 0.016
Small-cell anaplastic 4(4) 1 0.58(2.40-0.34) 0.034
carcinoma
Squamous cell carcinoma 5(8) 2 0.85(6.76-0.08a) 0.062
Carcinoma showing mixed l(1) 1 0.20a 0.006
differentiation
Totals 15(18) 9 0.49
Pleural mesotheliomas 3(4) 3 2.05(5.34-0.77) 0.060
a Samples that were negative in the scattering bioassay
Table II HGF/SF levels in pleural effusion fluids from patients with metastatic carcinoma, lymphoma, leukaemia or sarcoma
No. ofpatients No ofpatients where Median HGF/SF Mean HGF/SF
(no. ofsamples malignant cells levels ngmr' level per mg of
Tumour type in brackets) found in effusions (range in brackets) protein
Other adenocarcinomas
Adenocarcinoma of breast 6(7) 6 1.26 (2.42-0.27) 0.037
Adenocarcinoma of prostate 3(5) 2 1.07 (2.11-0.18) 0.031
Adenocarcinoma of colon 3(3) 2 0.64 (0.66-0.32) 0.015
Adenocarcinomas of known origin (various
types, -2 patients each) 5(8) 3 1.09 (4.57-0.36) 0.042
Totals 17(23) 13 1.03
Adenocarcinoma (origin uncertain or 9(11) 9 1.48 (4.31-0.40) 0.057
unknown)
Totals 26(34) 22 1.12
Malignant lymphomas
Non-Hodgkin's and Hodgkin's 6(6) - 0.84 (1.39-0.16a) 0.026
MALT-type lymphoma 1(1) 1 0.44 0.008
Totals 7(7) 1 0.47
Miscellaneous
Squamous cell carcinoma (oesophagus) 1(1) - 9.70 0.209
Carcinoma (origin unknown) 1(1) 1 0.46 0.013
Acute myeloblastic leukaemia 1(1) 11.02 0.49
Mediastinal embryonal rhabdomyosarcoma 1(1) 7.46 0.19
aSamples that were negative on the scattering bioassay.
primary lung carcinomas, malignant pleural mesotheliomas,
metastatic carcinomas, malignant lymphomas and miscella-
neous neoplasms.
It is clear that, judged by ELISA level, all but three samples
(64 out of 67) contained levels of HGF/SF above that
considered to be background (approximately 0.2 ng ml-1).
Turning first to primary lung carcinomas, samples were
obtained from patients with adenocarcinoma, squamous cell
carcinoma, small-cell anaplastic carcinoma and a single
carcinoma showing mixed differentiation. The median HGF/
SF ELISA for all primary lung carcinomas was found to be
0.49 ng ml-'. (Table I). Among the samples from the
squamous carcinoma patients, one (the last of four obtained
from the same patient) was much higher at 6.76 ng ml-' than
all the rest. Another sample from a different patient had an
HGF/SF titre of 4.15 ng ml-'. The samples for the lung
adenocarcinoma patients did not contain any high samples but
one was only just above the baseline and proved negative on
the scattering bio-assay (see below). One might expect higher
HGF/SF levels to be present in samples in which malignant
cells were identified but among the samples we assayed this
was not so. All the effusions from patients with adenocarci-
noma of the lung contained malignant cells but only in two
out of five patients with squamous cell carcinomas were
malignant cells found in an effusion. Among the squamous cell
carcinoma samples the first high ELISA sample (6.76 ng ml-')
did not contain malignant cells but the second high sample
(4.15 ngml- 1) did. Four samples were obtained from four
patients with small-cell anaplastic carcinoma with a median
HGF/SF level of 0.58 ng ml-'. Of these samples malignant
cells were found in only one. Pleural effusions were also taken
from three patients with malignant mesothelioma and, as
would be expected, malignant cells were found in all samples.
All the samples were positive for HGF/SF; the median
(2.05 ng ml-1) was the highest for any group of tumours.
(Table I).
The next category (other metastatic carcinomas) included
adenocarcinomas from a variety of known origins that had
metastasised to the pleura (Table II). Counting all the
samples from patients with non-bronchial adenocarcinomas,
a median ELISA of 1.12 ng ml-' was found. Among these
samples the most numerous main primary sites were breast,
prostate and colon. All the breast carcinoma samples were
found to contain significant levels of HGF/SF (median
1.26 ng ml-') but none was particularly high, the highest
level found being 2.42 ng ml-'. All the patients had
malignant cells in their effusions. The median
(1.07 ng ml-') and range of the samples from patients with
prostatic adenocarcinoma were rather similar while the few
(three) samples from patients with colonic adenocarcinoma
had a rather lower median (0.64 ng ml-'). One of the pleural
effusions from a patient with prostatic adenocarcinoma
proved to have a HGF/SF below baseline (0.18 ng ml-1)
but was just positive on the scattering bioassay. MalignantHGF/SF in pleural effusions
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Table III Comparison of HGF/SF ELISA and scattering bioassay
0
Well no. at which (No scattering
endpoint seen observed) 1 2 3 4 5 6
Median ELISA value of all
samples which correspond
to this well no. (ng ml-' 0.21 0.45 1.2 1.3 3.2 4.8 9.7
Range of ELISA values
from samples above (ng ml-1) 0.14-0.29 0.18-2.34 0.39-2.40 0.82-2.66 0.39-7.46 1.97-11.02 9.70-9.70
No. of samples analysed 6 33 29 14 12 5 1
cells were not seen in this sample nor were they seen in the
effusion from one of the colon carcinoma patients. Here, too,
a low ELISA value of 0.32 ng ml-' was found.
All 11 effusion samples obtained from patients with
adenocarcinomas of uncertain or unknown origin proved
positive for HGF/SF with a median ELISA of 1.48 ng ml-'.
For all the patients, malignant cells were seen in at least one
of these effusions. One sample had a high HGF/SF level of
4.31 ng ml-'.
The fourth class of tumours included several types of
malignant lymphomas. Six samples from seven patients
proved positive for HGF/SF and one negative for HGF/
SF, as judged both by scattering bioassay and ELISA
(median 0.47 ng ml-'). Only one sample, from a patient
with a mucosa associated lymphoid tissue (MALT)-type
lymphoma, contained malignant cells; samples from the other
six patients were negative in this respect.
The last, miscellaneous, group includes single samples from
several different types of malignant disease. There were
effusion samples from two other carcinomas, one ofunknown
origin and the other from a patient with a squamous cell
carcinoma of the oesophagus. The latter had a very high level
of HGF/SF (9.70 ng ml-'). Cancer cells were not seen in this
sample but, because of the proximity of the tumour to the
pleura, involvement was very likely. The effusion from the
patient with acute myeloblastic leukaemia had a very high
HGF/SF ELISA of 11.0 ng ml-1, the highest ofall the samples
seen. No malignant cells were found in this sample. However,
the patient was suffering from a severe chest infection due to
immunocompromise. The last class of malignant tumour in
our samples was represented by pleural effusion fluid from one
patient with a mediastinal embryonal rhabdomyosarcoma.
Here an ELISA of 7.46 ng ml-1 was recorded, the second
highest for all the cancer patients. Malignant cells were not
seen in the effusion fluid of this patient but extensive
involvement of the pleura was observed upon thoracoscopy.
A major question in a study such as this is how well HGF/
SF levels measured immunologically correspond to biological
activity. To answer this, 90 effusion samples from the cancer
patients (and also some other non-cancer patients) were
tested on the scattering bioassay. The data are presented as
Table III. All the ELISA samples, except one, below a
baseline of 0.2 ng ml-' corresponded to clear-cut negatives
on the scattering bioassay. The single positive (ELISA
0.18 ng ml-') corresponded to an end point at the lowest
dilution tested. Three samples with an ELISA slightly above
0.2 ng ml-' showed no scattering (0.28, 0.25 and 0.22 ng
ml-'). Two others were positive (0.28 and 0.27 ng ml-') at
the lowest dilution, so for pleural effusion fluids an ELISA
baseline of about 0.25 ng ml-' corresponded very well with
the detection of scattering activity at the limit. A Spearman
rank correlation analysis was carried out to compare the
ELISA and scattering bioassays and a strong rank
correlation was obtained with a coefficient of 0.82. Given
the non-quantitative nature of the scattering bioassay (which
depends on visual inspection) the medians of the ELISAs
would seem to correspond moderately well with each
doubling dilution, although wide ELISA ranges were found
to correspond to each end point.
During the course of the above comparison it became
obvious that a small number of exceptions occurred. In each
case no scattering was observed, even though significant
amounts of HGF/SF were present, as identified by ELISA.
All these effusions caused an inhibition of cell attachment,
and also seemingly of cell division, leading to only few
isolated cells being present in the wells. A very similar
inhibition of the attachment and growth of MDCK cells was
found when testing human serum in the scattering bioassay.
The nature of this inhibitor remains to be determined.
Among the effusions causing inhibition three out of five
samples were from lymphoma patients (the other two being
from a metastatic breast carcinoma and a metastatic
adenocarcinoma of unknown origin). However, the other
lymphoma effusions were clearly positive on the bioassay and
did not show any evidence ofinhibitory effects. There was no
obvious difference between these samples and the others and
the usual range of protein concentrations were observed.
Discussion
The origin of HGF/SF within pleural effusionsfrom cancer
patients
Pleural effusion fluids are complex protein-rich fluids
(Paddock, 1940; Light et al., 1972). Not infrequently such
effusions are bloody and contain material from the
pulmonary or pleural microvasculature. In this study we
have demonstrated that most pleural effusion fluids in
patients with malignant disease contain significant quantities
of HGF/SF, a potent promoter of cell growth and motility.
There are several possible origins, not necessarily mutally
exclusive, for this activity.
There is in vitro evidence that certain classes of primary
lung tumours may secrete HGF/SF and that this may act as
an autocrine growth promoter. Tsao et al. (1993) found that
most of a panel of non-small cell lung (NSCL) carcinoma
lines, and also normal bronchial epithelial cells, secreted
HGF/SF and expressed c-met. Yoshinaga et al. (1992) also
found two NSCL carcinoma cell lines which synthesised
HGF/SF. In contrast Rygaard et al. (1993a) found that only
2 out of 25 small-cell lung carcinoma (SCLC) lines contained
HGF/SF transcripts, and of these only one also expressed c-
met. However, a number of SCLC cell lines are scattered by
HGF/SF and thus can respond to the factor (Rygaard et al.,
1993b). At present very few epithelial cell lines have been
found to secrete HGF/SF and the general conclusion is that
the factor is much more usually a paracrine effector
(Gherardi et al., 1993; Sonnenberg et al., 1993).
A second possibility is that the tumour stroma may secrete
HGF/SF. A number of human lung fibroblast lines of
various origins secrete HGF/SF in culture (see Gherardi et
al., 1993) so this is a possible source of at least some of the
HGF/SF in the pleural effusions. Inflammatory cytokines,
including interleukin 1 and tumour necrosis factor, are
known significantly to enhance HGF/SF production by
fibroblasts in culture obtained from a variety of sources
(Tamura et al., 1993). Similar mechanisms may well occur in
vivo.
A third possible origin of the HGF/SF is that it is derivedHGF/SF in pleural effusions
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from the lung as part of a host tissue response to the growing
tumour. There is experimental evidence that the induction of
lung damage is rapidly followed by HGF/SF synthesis within
the lung. Yanagita et al. (1993) injected hydrochloride into
the tracheas of rats and found a rapid appearance of HGF/
SF transcripts followed by an increase in HGF/SF activity. It
seems likely that HGF/SF is secreted in response to damage
and disease. This could well occur during tumorigenesis in
the lung.
The final potential origin is that some of the HGF/SF
found in the effusions is secreted into the blood by other
organs, in particular the liver. The mechanism for this would
be that the secreted HGF/SF enters the general circulation
and escapes into the pleural fluid via capillary damage due to
the tumour, or localised inflammation. At present there is no
evidence that this occurs, although it cannot be excluded.
Recent experimental evidence has demonstrated that the
reverse can occur. For rats it has been found that partial
hepatectomy is followed by a rapid increase in blood HGF/
SF levels due to its synthesis by other tissues, including the
lung (Kinoshita et al., 1991). At present we cannot
distinguish the potential contributions from the different
possible sources of HGF/SF described above; it will be
necessary to directly identify which cells within the lungs
secrete HGF/SF.
So far only one study has been made of the location of
HGF/SF within the lungs. This was of patients with primary
lung tumours and done using immunocytochemistry of fixed
materal (Yoshinaga et al., 1993). Much of the HGF/SF was
found to be associated with extracellular matrix material,
particularly the basement membranes of tumour cells and
also of the adjacent bronchial epithelium. These authors
proposed that much of the observed HGF/SF was bound to
heparin. Our results demonstrate that significant amounts of
soluble HGF/SF are present in the tumour environment of
the lung, at least in cases in which the pleura is involved, and
probably more widely.
Comparison ofHGF/SF levels associated with different tumour
types
The levels of HGF/SF pleural effusion fluids from patients
with various types of malignant disease varied widely. A
trivial explanation could be that the amount of HGF/SF
present simply reflected the protein concentration. However,
measurement of the latter in samples showed no such
correlation. Samples with the same protein concentration
were found to have up to a 10-fold difference in HGF/SF
concentrations.
The most interesting comparison between tumour classes
was that between the median HGF/SF ELISA value of
primary lung adenocarcinomas and that of all metastatic
adenocarcinomas. Although the sample sizes were small, the
range for the lung adenocarcinomas was much less than the
much bigger range for all metastatic adenocarcinomas,
including two high values above 4ngml-. It may be that
metastic adenocarcinomas can induce higher levels of HGF/
SF within the pleural effusions. Taniguchi et al. (1994) have
reported a significant difference ofmean HGF/SF serum levels
from primary breast cancer patients as compared with samples
from patients with recurrent breast cancer. They suggested
that this increase was associated with tumour progression,
particularly when metastases to the liver occurred.
A comparison of the different classes of primary lung
tumours showed quite large differences but these were not
statistically significant, possibly because ofthe large variances
found. Indeed the large variation in HGF/SF levels was a
consistent feature seen for all the types of tumours recorded.
There was no obvious correlation of HGF/SF levels with the
presence or absence ofmalignant cells, rather the presence or
absence of malignant cells depended upon tumour type.
Thus, as would be expected, all the mesothelioma and lung
adenocarcinoma samples contained malignant cells but only
roughly half of the lung squamous cell carcinoma samples
and one-quarter of the small-cell anaplastic carcinoma
samples did so. Adenocarcinoma of the lung frequently
develops peripherally whereas small cell anaplastic and
squamous cell carcinomas are usually more central in origin
(Mooi and Addis, 1990). Nearly all the pleural effusions from
lymphoma patients did not contain malignant cells and it
seems likely that these effusions were more likely due to
changes in the blood circulatory system rather than
pulmonary invasion. Significant amounts of HGF/SF have
been found in the blood and bone marrow plasma of various
types of leukaemia and lymphoma patients (Nakamura et al.,
1994) and the HGF/SF may be secreted by lymphoma or
leukaemia cells. In conclusion, no simple reason can be
deduced for the variation in HGF/SF levels. It may reflect
the degree of lung damage, the amount of HGF/SF synthesis
by the tumour or the stroma, or perhaps by some class of
white blood cell or a combination of factors.
Possible biological significance of the HGF/SF levelsfound in
pleural effusions
The major finding of this study is that over 90% of the
pleural effusions from patients with different kinds of
malignant disease, invading the lung and/or pleura, con-
tained detectable amounts of HGF/SF. This raises the
question of the possible biological effects of these levels of
HGF/SF on tumour growth and spread. The levels of HGF/
SF present in the pleural fluids can be compared with in vitro
data for mitogenic stimulation and scattering. The mitogenic
activity of hepatocytes and many other epithelial cell types,
including several lung cell lines, can be stimulated in a dose-
dependent manner with half-maximal stimulation in the
range 0.3-2 ng ml-' (Nakamura et al., 1987; Gohda et al.,
1988). Furthermore, we have determined that scattering is
first stimulated in culture at around 0.25 ng ml-'. Thus the
levels of HGF/SF found in the pleural effusion fluids are
clearly similar to the amounts sufficient to cause mitogenesis
and scattering in vitro.
A number of in vitro and in vivo studies have shown that c-
met is frequently expressed in both non-small cell (Tsao et al.,
1993) and small-cell carcinoma cell lines (Rygaard et al.,
1993a) and in a range of tumour types including lung
carcinomas (di Renzo et al., 1991; Prat et al., 1991).
Therefore, if, as we have demonstrated in pleural effusions,
free HGF/SF is present within the lung around any tumour
cells carrying c-met, then the cells will probably respond to it.
In consequence, the presence of c-met on the surfaces of lung
tumours may prove to be important for future cancer therapy
strategies. However, caution is required before drawing any
general conclusions relating c-met activation to enhanced
mitosis and/or scattering. HGF/SF also induces tubulogenesis
of MDCK cells when grown in suspension within collagen
gels (Montesano et al., 1991). This is a differentiation event,
but one linked with mitogenesis. HGF/SF can also inhibit
rather than enhance the growth rates of certain cell lines in
culture (Higashio et al., 1990; Tajima et al., 1991; Jiang et al.,
1993) and this list now includes SCLC lines (Rygaard et al.,
1993b). At high concentrations (above 5 ng ml-') stimulation
of the growth of human biliary cells passes into inhibition
(Strain et al., 1991). Therefore HGF/SF is a bidirectional
growth regulator and not just a mitogen. In spite of these
qualifications it is clear that tumour cells growing within the
pleura and adjacent lung tissue may be exposed to varying
but biologically significant levels of HGF/SF. Study now
must be made of which cell types within the lung secrete
HGF/SF and the varying ways in which tumour cells,
particularly those of the lung and pleura, may respond to it.
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